Safety Study of CC312 in Autoimmune Disease Patients — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Safety Study of CC312 in Autoimmune Disease Patients — Stella

Recruiting

Back to Systemic Lupus Erythematosus (SLE) trials

Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.

Trial locations(1 site)

China

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China

Key details

Phase

Very early testing

Sponsor

CytoCares Inc

Enrollment target

~18 participants

Started

November 2024

Primary completion

November 2026

Age range

18 Years and older

Last updated September 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov